Your session is about to expire
← Back to Search
MDNA11 + Pembrolizumab for Cancer (ABILITY-1 Trial)
ABILITY-1 Trial Summary
This trial is testing a new drug to treat cancer. The drug is given alone or with another drug. The study will see how well the drug works and how safe it is.
ABILITY-1 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.ABILITY-1 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I received my last cancer treatment within the required timeframe.I have brain metastases but they are stable after treatment.I have received an organ or tissue transplant from another person.I am not on long-term steroids or immunosuppressants.I do not have an active autoimmune disease that could worsen with immunotherapy.I do not have severe lung, heart, or other systemic diseases.I am not pregnant, breastfeeding, nor planning to become pregnant during the study.I am currently on medication for an infection.My cancer is advanced or has spread and confirmed by lab tests.My organs are functioning well.My cancer can be measured and has been confirmed by a scan.I am not pregnant, have tested negative for pregnancy, and am not breastfeeding.I am 18 years old or older.I am fully active or can carry out light work.I haven't had any cancer other than the one being treated in this study in the last 3 years.My cancer can be measured by scans.You are expected to live for at least 12 weeks.My cancer is advanced, cannot be surgically removed, and has been confirmed by lab tests.
- Group 1: MDNA11
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are researchers actively seeking participants for this trial?
"Clinicaltrials.gov indicates that this medical investigation is actively recruiting participants, having initially been uploaded to the portal on August 27th 2021 and last edited on November 1st 2022."
What is the magnitude of individuals involved in this study?
"This medical trial necessitates the recruitment of 100 eligible individuals. Those wishing to join must meet certain requirements, and can do so at Gabrail Cancer Center Research in Canton, Ohio or Emory - Winship Cancer Institute in Atlanta, Georgia."
What objectives has this research endeavor set out to fulfill?
"According to the trial sponsor, Medicenna Therapeutics, Inc., one of their primary objectives is to identify MDNA11's Recommended Phase 2 Dose (RP2D) over a period of 12 months. Similarly, they are also assessing secondary metrics such as Time to Maximum Observed Serum Drug Concentration (Tmax), Area Under The Serum Concentration vs Time Curve From Time Zero To Last Measurable Concentration (AUClast), and Pharmacodynamic Effects Of MDNA11 Via Flow Cytometry Analysis Of Immune Cells In Blood And Measurements Of Cytokine Levels."
Is this the inaugural trial of its kind?
"Currently, 156 active clinical trials for MDNA11 Monotherapy are taking place across 34 nations and 929 cities. The inaugural trial under Key Biologics LLC began in 2006, with 1230 participants completing Phase 2 drug approval. Subsequent to this initial study, a total of 220 further experiments have been completed."
Could you elucidate on any prior research involving the application of MDNA11 Monotherapy?
"Initially developed in 2006 at The University of Texas MD Anderson Cancer Center, 220 clinical trials have already been completed for MDNA11 Monotherapy. At present, 156 studies are still ongoing with a large portion being conducted out of Canton, Ohio."
How widespread is the implementation of this trial in our urban area?
"This research study is conducted across 6 sites, including Canton, Atlanta and Boca Raton. To reduce the burden of added travel expenses when enrolling in this trial, patients should choose a medical centre that is closest to them."
What medical ailments does MDNA11 Monotherapy typically treat?
"MDNA11 Monotherapy is a known remedy for peritonitis and has also been effective in treating liver failure, prevention of hypovolemia, and adult respiratory distress syndrome."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger